These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11763339)

  • 1. The scientific basis for stopping polio immunisation--issues and challenges.
    Wood DJ
    Dev Biol (Basel); 2001; 105():69-72. PubMed ID: 11763339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible global strategies for stopping polio vaccination and how they could be harmonized.
    Cochi SL; Sutter RW; Aylward RB
    Dev Biol (Basel); 2001; 105():153-8; discussion 159. PubMed ID: 11763323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strengths and weaknesses of current polio vaccines--a view from industry.
    André FE
    Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stopping poliovirus vaccination after eradication: issues and challenges.
    Wood DJ; Sutter RW; Dowdle WR
    Bull World Health Organ; 2000; 78(3):347-57. PubMed ID: 10812731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?
    Khan MM
    Vaccine; 2008 Apr; 26(16):2034-40. PubMed ID: 18339460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating vaccine-derived polioviruses: current state of knowledge.
    Kew OM; Wright PF; Agol VI; Delpeyroux F; Shimizu H; Nathanson N; Pallansch MA
    Bull World Health Organ; 2004 Jan; 82(1):16-23. PubMed ID: 15106296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative.
    Fine PE; Carneiro IA
    Am J Epidemiol; 1999 Nov; 150(10):1001-21. PubMed ID: 10568615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A vision of a world without polio: the OPV cessation strategy.
    Heymann DL; Sutter RW; Aylward RB
    Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.
    Friedrich F
    Acta Virol; 2000 Apr; 44(2):109-17. PubMed ID: 10989702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polio control after certification: major issues outstanding.
    Fine PE; Oblapenko G; Sutter RW
    Bull World Health Organ; 2004 Jan; 82(1):47-52. PubMed ID: 15106300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interrupting wild poliovirus transmission using oral poliovirus vaccine: environmental surveillance in high-risks area of India.
    Chowdhary R; Dhole TN
    J Med Virol; 2008 Aug; 80(8):1477-88. PubMed ID: 18551602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on vaccine-derived polioviruses.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(40):1093-7. PubMed ID: 17035927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intense campaign for vaccination with the oral polio vaccine: what are the repercussions on the enterovirus world?].
    Delpeyroux F; Guillot S; Szendröi A; Balanant J; Caro V; Cuervo N; Chevaliez S; Dahourou G; Crainic R
    Bull Soc Pathol Exot; 2000 Jul; 93(3):193-7. PubMed ID: 11030056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of reintroduction of polio after eradication: the vaccine origin of an outbreak of type 3 poliomyelitis.
    Martin J; Ferguson GL; Wood DJ; Minor PD
    Dev Biol (Basel); 2001; 105():83-92. PubMed ID: 11763341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Childhood mortality after oral polio immunisation campaign in Guinea-Bissau.
    Aaby P; Hedegaard K; Sodemann M; Nhante E; Veirum JE; Jakobsen M; Lisse I; Jensen H; Sandström A
    Vaccine; 2005 Feb; 23(14):1746-51. PubMed ID: 15705481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.